BioCentury
ARTICLE | Clinical News

MGI Pharma to start pancreatic cancer Phase III

October 23, 2000 7:00 AM UTC

MOGN said it will begin by year end U.S. Phase III testing of its Irofulven hydroxymethylacylfulvene ( MGI 114) compound in patients with advanced pancreatic cancer with disease progression following ...